Skip to main content

Pharmacokinetic interactions between the potential COVID-19 treatment drugs lopinavir/ritonavir and arbidol in rats






洛匹那韦/利托那韦联合阿比多尔作为国内多家医疗单位治疗 COVID-19 患者的基础抗病毒方案, 两者的药物相互作用未有研究报道, 本论文通过开展体内药动学实验, 探索合用后药物体内暴露量的改变, 为该方案的临床治疗有效性和安全性提供保障.


建立大鼠洛匹那韦/利托那韦与阿比多尔药动学相互作用模型. 将大鼠分为3组(阿比多尔组、洛匹那韦/利托那韦组及联用组). 洛匹那韦/利托那韦和阿比多尔分别以50 mg/kg/12.5 mg/kg和25 mg/kg灌胃给药. 采用液相色谱串联质谱 (LC-MS/MS) 法测定洛匹那韦和阿比多尔的浓度.


洛匹那韦/利托那韦联合阿比多尔治疗后, 阿比多尔的药时曲线下面积 (AUC) 和洛匹那韦的峰浓度 (Cmax) 显著升高. 这两种药物的相互作用可能会影响联合治疗的安全性. 因此, 洛匹那韦/利托那韦与阿比多尔同时给药时, 建议适当调整给药剂量, 阿比多尔的剂量可能需要减半.


  1. Cai QX, Huang DL, Yu H, et al., 2020a. COVID-19: abnormal liver function tests. J Hepatol, 73(3):566–574.

    CAS  Article  Google Scholar 

  2. Cai QX, Yang MH, Liu DJ, et al., 2020b. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing), 6(10):1192–1198.

    CAS  Google Scholar 

  3. Cao B, Wang YM, Wen DN, et al., 2020. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med, 382(19):1787–1799.

    Article  Google Scholar 

  4. Deng LS, Li CN, Zeng Q, et al., 2020. Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort study. J Infect, 81(1):E1–E5.

    CAS  Article  Google Scholar 

  5. Gao JJ, Tian ZX, Yang X, 2020. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends, 14(1):72–73.

    CAS  Article  Google Scholar 

  6. Gautret P, Lagier JC, Parola P, et al., 2020. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents, 56(1): 105949.

    CAS  Article  Google Scholar 

  7. Grein J, Ohmagari N, Shin D, et al., 2020. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med, 382(24):2327–2336.

    CAS  Article  Google Scholar 

  8. Guo YZ, Xu KJ, Li YT, et al., 2020. Safety of protease inhibitors and Arbidol for SARS-CoV-2 pneumonia in Zhejiang Province, China. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 21(12):948–954.

    CAS  Article  Google Scholar 

  9. Jiang SP, Wang RR, Li L, et al., 2020. Liver injury in critically ill and non-critically ill COVID-19 patients: a multicenter, retrospective, observational study. Front Med (Lausanne), 7:347.

    Article  Google Scholar 

  10. Jullien V, Urien S, Hirt D, et al., 2006. Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years. Antimicrob Agents Chemother, 50(11):3548–3555.

    CAS  Article  Google Scholar 

  11. LiverTox, 2012. Clinical and research information on drug-induced liver injury: protease inhibitors (HIV). Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases.

    Google Scholar 

  12. Ofotokun I, Chuck SK, Binongo JN, et al., 2007. Lopinavir/ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy. J Clin Pharmacol, 47(8):970–977.

    CAS  Article  Google Scholar 

  13. Umeh OC, Currier JS, Park JG, et al., 2011. Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men. J Clin Pharmacol, 51(12): 1665–1673.

    CAS  Article  Google Scholar 

  14. Wang ZL, Yang BH, Li QW, et al., 2020. Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis, 71 (15):769–777.

    CAS  Article  Google Scholar 

  15. Xu KJ, Cai HL, Shen YH, et al., 2020. Management of COVID-19: the Zhejiang experience. J Zhejiang Univ (Med Sci), 49(2):147–157 (in Chinese).

    Google Scholar 

  16. Zhang C, Shi L, Wang FS, 2020. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol, 5(5):428–430.

    Article  Google Scholar 

Download references


This work is supported by the National Natural Science Foundation of China (No. 81703612).

Author information



Corresponding author

Correspondence to Saiping Jiang.

Additional information

Author contributions

Yunzhen HU, Saiping JIANG, and Xiaoyang LU conceived and designed this study. Minjuan ZUO and Xiaojuan WANG carried out the experiments. Yunzhen HU performed data analysis and drafted the manuscript. Rongrong WANG and Lu LI made critical contribution to the discussion. All authors have read and approved the final manuscript and, therefore, have full access to all the data in the study and take responsibility for the integrity and security of the data.

Compliance with ethics guidelines

Yunzhen HU, Minjuan ZUO, Xiaojuan WANG, Rongrong WANG, Lu LI, Xiaoyang LU, and Saiping JIANG declare that they have no conflict of interest.

The Research Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine (Hangzhou, China) approved the protocol followed in this study. All institutional and national guidelines for the care and use of laboratory animals were followed.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hu, Y., Zuo, M., Wang, X. et al. Pharmacokinetic interactions between the potential COVID-19 treatment drugs lopinavir/ritonavir and arbidol in rats. J. Zhejiang Univ. Sci. B 22, 599–602 (2021).

Download citation


  • 药代动力学
  • COVID-19
  • 相互作用
  • 洛匹那韦/利托那韦
  • 阿比多尔